CDC: In 2023, age-adjusted prevalence of U.S. adults (>20 yrs) with obesity was 40.3% (9.7% with severe obesity; 31.7% overweight). BMI data from NHANES, & the National Center for Health Statistics https://t.co/kH9ajbUJ2m https://t.co/utbGWf4D12

• stats

Korean Insurance claims nested case–control study of 27,410 RA pts - 5482 w/ > comorbid Dsx Vs 21,928 w/ < 10 comorbd Dz. Having >10 signif incr Serious infx (OR 1.44), opportunistic (21.9)& Hzoster (1.18); mainly skin & soft tissue infx - NOT fatal infx. https://t.co/qDrU3BXYzd

What’s New PsA? (4.3.2026) Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials. https://t.co/Ew1wAFDfa1 https://t.co/AJfqqEAdik

• What’s New PsA? (4.3.2026) | RheumNow

Machine learning predicts macrophage activation syndrome in adult Still's disease - 312 AOSD - XGBoost model had 5 predictors: ferritin, splenomegaly, Plt#, cholesterol, & ESR (AUC 0.839, sensit 0.824, specificity 0.710. https://t.co/QrogaCYPCT https://t.co/Z6WgCnFTfx

• Machine learning for predicting macrophage activation syndrome in adult patient…

Danish real-world study anifrolumab use in 36 #SLE pts. SLEDAI-2K decreased from 8 (baseline) to 2 @ mos 3; @6 mos 52% had SLEDAI-2K=0. 87% had PGA ≤0.5 w/ LLDAS, & 70% DORIS remission. Pred use declined by >50%. Herpes infx were most freq AE https://t.co/tbMOyOioeU https://t.co/jDJgImjgQt

• Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective …

Phase 1b trial shows transdermal Curcumin Gel (VAS-101) in was effective in Knee Osteoarthritis. Enrolled 60 KOA pts 45–75 yrs Rx w/ PBO or gel qd x 28d w/ signif improvement in pain & KOOS scores https://t.co/yNiNocZxa4 https://t.co/3W7j1bIvBc

• Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curc…

UK Our Future Health study of 1,563,155 finds affective Dz (depression, bipolar, anxiety) signific higher (p<0.001)in autoimmune pts vs gen. pop. (29% vs 18%) - dx by PHQ-9, GAD-7. (OR 1.86), even after adjustments income and pain, etc. https://t.co/HoKBeAZxbS https://t.co/LnC4lqqgq7

• Affective disorders and chronic inflammatory conditions: analysis of 1.5 millio…

Korean study 50600 adult RA pts (Dx 2010-2020) shows Sustained high-income was assoc w/ reduced mortality, esp in younger pts (adj HR 0.50 <65 years vs 0.74 ≥65 years). Amplifed by Rural residence https://t.co/DUZoNsPSHj https://t.co/PV3Umlrgvv

• https://buff.ly/anePJHD

There is very little evidence that kinesio taping has any true benefits in patients with musculoskeletal disorders https://t.co/3HIJOljacA https://t.co/Xz1YvQtHGs

• Effectiveness and clinical relevance of kinesio taping in musculoskeletal disor…

1/3 of American adults have poor sleep. New survey from Amer. Academy Sleep Medicine shows 45% of pts never discuss sleep issues with their doctors; only 15% discussed it with a sleep specialist. https://t.co/uvlHjpuVs8 https://t.co/fDOtp9rxOn

• Missing From Most Doctor-Patient Talks: Sleep Issues

Update on Primary CNS Angiitis The Journal of Neurology has posted a review and update of Primary CNS vasculitis (PCNSV), also termed primary angiitis of the CNS (PACNS). PCNSV is rare, potentially fatal, and highly treatable, making timely recognition and accurate diagnosis https://t.co/cjGX1ig8Lp

Open label RCT in 116 DMARD-naïve #RA pts Rx w/ tofacitinib or MTX (after 1 IM steroid injx). @3 mos, TOFA signif better than MTX for >50% SDAI improv(94 v 75%), CDAI[14.5 v 7.3), DAS28-CRP[1.7 v 1.2] https://t.co/smOuLlVFyX https://t.co/xGvbiu62OB

• Redefining Initial Rheumatoid Arthritis Treatment: Tofacitinib Outperforms Meth…